Hussman Strategic Advisors Inc. Has $2.10 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Hussman Strategic Advisors Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 50.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,000 shares of the biotechnology company’s stock after selling 63,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in Exelixis were worth $2,098,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in EXEL. USA Financial Formulas acquired a new stake in shares of Exelixis in the 4th quarter worth about $32,000. Principal Securities Inc. raised its holdings in shares of Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares during the last quarter. Kestra Investment Management LLC acquired a new stake in shares of Exelixis in the 4th quarter worth about $39,000. Brooklyn Investment Group acquired a new stake in shares of Exelixis in the 3rd quarter worth about $42,000. Finally, UMB Bank n.a. raised its holdings in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EXEL. Brookline Capital Management began coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. Wells Fargo & Company increased their price objective on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Truist Financial increased their price objective on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Insiders Place Their Bets

In related news, EVP Patrick J. Haley sold 10,000 shares of Exelixis stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total value of $352,700.00. Following the transaction, the executive vice president now owns 278,665 shares in the company, valued at $9,828,514.55. This trade represents a 3.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,210 shares of company stock worth $2,978,785 in the last three months. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Trading Up 2.5 %

EXEL opened at $35.07 on Thursday. The company has a 50 day moving average of $34.16 and a 200 day moving average of $31.11. The company has a market cap of $9.82 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $37.59.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.